Antiviral treatment of chronic hepatitis B with lamivudine in pediatric renal transplantation

Abstract: Renal transplantation in patients with chronic hepatitis B virus (HBV) infection is known to be associated with an increased risk for exacerbation of liver dysfunction. Lamivudine has been proven to be a potent inhibitor of hepatitis B virus replication in adults after kidney transplantation. Little is known about its efficacy and safety in pediatric renal transplant recipients. Three cases serve for the discussion to demonstrate the complexity of the clinical course and effective treatment of chronic hepatitis B in pediatric patients awaiting renal transplantation. Two patients on dialysis with a high HBV replication rate were treated with lamivudine before transplantation. After the viral load had decreased below the detection limit, they underwent transplantation successfully. Despite intensified immunosuppression to treat a rejection episode in one and a relapse of the nephrotic syndrome in the other patient, the viral load remained <2.5 pg/mL. Both patients developed a mutation in the YMDD motif of the HBV genome associated with an increase in the HBV replication rate >10 000 pg/mL without deterioration of the liver function.

[1]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[2]  F. Fabrizi,et al.  Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials , 2004, Transplantation.

[3]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[4]  E. Gane,et al.  Management of chronic viral hepatitis before and after renal transplantation , 2002, Transplantation.

[5]  F. Fabrizi,et al.  Management of hepatitis B after renal transplantation: an update. , 2002, Journal of nephrology.

[6]  Chi-hung Cheng,et al.  Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  V. Bain.  Hepatitis B in transplantation , 2000, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  R. Tur-kaspa,et al.  An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation , 2000, American Journal of Gastroenterology.

[9]  E. Puchhammer-Stöckl,et al.  TWELVE MONTHS OF LAMIVUDINE TREATMENT FOR CHRONIC HEPATITIS B VIRUS INFECTION IN RENAL TRANSPLANT RECIPIENTS12 , 2000, Transplantation.

[10]  Y. Chrétien,et al.  HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. , 2000, Transplantation.

[11]  S. Locarnini,et al.  Antiviral chemotherapy for the treatment of hepatitis B virus infections. , 2000, Gastroenterology.

[12]  C. Lo,et al.  Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians. , 1999, Transplantation proceedings.

[13]  K. Chayama,et al.  Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.

[14]  K. Reddy,et al.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation , 1997, The Lancet.

[15]  C. Fairley,et al.  The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. , 1991, Transplantation.

[16]  L. Poellinger,et al.  The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. , 1988, Virology.

[17]  G. Mayer,et al.  ADVERSE EFFECT OF LOW‐DOSE PROPHYLACTIC HUMAN RECOMBINANT LEUKOCYTE INTERFERON‐ALPHA TREATMENT IN RENAL TRANSPLANT RECIPIENTS: Cytomegalovirus Infection Prophylaxis Leading to an Increased Incidence of Irreversible Rejections , 1988, Transplantation.

[18]  P. Parfrey,et al.  HEPATITIS B DISEASE IN DIALYSIS AND TRANSPLANT PATIENTS FURTHER EPIDEMIOLOGIC AND SEROLOGIC STUDIES , 1987, Transplantation.

[19]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.